Three High-Yield Names Draw Cash Away From the AI Trade
AT&T, ONEOK and Pfizer offer yields spanning 4.3% to 6.1% and three different ways of returning cash — here is how their payout strategies and Monday's tape compare.
AT&T, ONEOK and Pfizer were flagged as dividend payers offering yields between 4.3% and 6.1% as investors hedge against AI-trade valuation worries, with T at $25.89, OKE at $96.01 and PFE at $28.46 as of 20:00 GMT on Aug. 31, 2026.
Income is back in the conversation. With valuations across the artificial-intelligence complex drawing more scepticism than applause, a group of large, cash-generative dividend payers is getting a second look from investors who would rather be paid to wait. Three names sit at the centre of that rotation: AT&T Inc. (NYSE: T), ONEOK Inc. (NYSE: OKE) and Pfizer Inc. (NYSE: PFE), which between them offer yields running from 4.3% to 6.1%.
What makes the trio interesting is not that they all pay well. It is that they pay well for entirely different reasons, out of entirely different kinds of cash flow, and with entirely different track records of raising, holding or resetting the dividend. An income investor buying all three is not making one bet three times — they are making three bets that happen to share a payout profile.
Monday's tape favoured the payers, unevenly
The market data tells a mixed story about how the rotation is actually playing out. As of the last trade at 20:00 GMT on Aug. 31, 2026, Pfizer changed hands at $28.46, up 1.79% on the day and near the upper end of a $27.64–$28.70 range. ONEOK traded at $96.01, up 1.32%, off an intraday high of $97.48. AT&T was the laggard, at $25.89, down 0.46% from a prior close of $26.01 and sitting close to its session low of $25.86.
Against that, the broad benchmarks were soft. The S&P 500 proxy SPY was at $767.02, down 0.30%, and the Dow 30 proxy DIA fell 0.65% to $531.57. The Nasdaq 100 proxy QQQ was essentially flat at $716.76, up 0.05%. In other words, two of the three income names outperformed all three major benchmarks on the session, while the tech-heavy index refused to break down. That is the shape of a hedge being put on at the margin, not a wholesale flight from growth.
Three different machines for producing cash
The yields cited — a 4.3% to 6.1% band, as flagged by MarketBeat — are wide enough that the top of the range pays roughly 42% more income per dollar invested than the bottom, on an illustrative basis. That gap is the market's own verdict on risk, and it is worth understanding what drives it in each case.
AT&T is a subscription business. Its cash comes from millions of monthly wireless and broadband bills, which is about as predictable a revenue base as exists in the listed market. The offset is capital intensity: fibre builds and spectrum are expensive, and the telecom sector carries the memory of a dividend that was reset once already. For income buyers, the relevant question is not whether the cash arrives — it does — but how much of it the network consumes before it reaches shareholders.
ONEOK is a midstream energy operator, meaning it moves and processes hydrocarbons rather than drilling for them. The economics are fee-based rather than price-based, which historically dampens the swing that commodity producers experience when crude and gas move. Midstream has been the most reliable source of high headline yield in the US market for years, and it is also where investors have most often been burned when leverage climbs faster than throughput.
Pfizer is the pharmaceutical case, and it is the most binary of the three. Drug companies generate enormous gross margins from patented products and then face cliffs when those patents expire. A high yield on a pharma name is usually the market pricing in a pipeline question rather than a balance-sheet one. Pfizer's 1.79% gain on Monday was the largest single-day move among the three, which suggests sentiment there is more volatile — for better and worse — than in the utility-like telecom or the toll-road midstream.
What separates a durable yield from a warning sign
The discipline for anyone buying into this band of yields is the same regardless of sector. Start with coverage: how much of the free cash flow the company generates is consumed by the dividend. A payout that eats most of the cash leaves nothing for debt reduction, buybacks or a downturn. Then look at what the company does with what is left. A firm paying down leverage is quietly strengthening the dividend even if it never raises it; a firm borrowing to top up the distribution is doing the opposite.
The discipline for anyone buying into this band of yields is the same regardless of sector.
Growth history is the third leg. A yield of 6.1% that has been static for years delivers less real income over a decade than a 4.3% yield that compounds. Investors reaching for the top of the range should be clear-eyed that they are usually trading future increases for current income, and that the market has priced it that way deliberately.
There is also a rate dimension. High-yield equity competes directly with fixed income, and the appeal of a 4.3% dividend depends heavily on what a Treasury pays for the same money with none of the equity risk. When yields on government paper fall, the payers re-rate upward; when they rise, the payers face a headwind that has nothing to do with their operations.
What to watch from here
The near-term test is whether the AI complex keeps holding up. QQQ's flat close against a falling Dow suggests the growth trade has not cracked — it has simply stopped leading. Should that change, the rotation into income names would likely accelerate, and the highest-yielding of the three would probably move most.
For each company individually, the checkpoints are concrete. For AT&T, capital spending and subscriber trends. For ONEOK, volumes across its systems and the leverage ratio. For Pfizer, pipeline milestones and how the company funds its distribution through patent transitions. None of those will show up in a single day's price action, which is precisely the point: the case for holding a dividend payer is a multi-year one, and the yield is the compensation for the wait.
Investors should also note that all three trade well below the level of the benchmark ETFs quoted here, which is a function of share price alone and says nothing about value. What matters is the cash returned per dollar committed, and on that measure the three-name group makes a coherent, if not identical, argument.
Key facts
- Yield range across the three names: 4.3% to 6.1%
- AT&T (NYSE: T): $25.89, -0.46%, as of 20:00 GMT Aug. 31, 2026
- ONEOK (NYSE: OKE): $96.01, +1.32%, as of 20:00 GMT Aug. 31, 2026
- Pfizer (NYSE: PFE): $28.46, +1.79%, as of 20:00 GMT Aug. 31, 2026
Frequently asked questions
Which three dividend stocks are named in this story?
AT&T, ONEOK and Pfizer. The three were flagged together as high-yield dividend payers offering yields spanning 4.3% to 6.1%, each using a distinct capital-return strategy. They span telecommunications, midstream energy and pharmaceuticals respectively, so an investor holding all three is diversified by sector while concentrated by payout profile.
How did the three stocks trade on Aug. 31, 2026?
As of the last trade at 20:00 GMT, Pfizer was at $28.46, up 1.79%; ONEOK was at $96.01, up 1.32%; and AT&T was at $25.89, down 0.46%. Two of the three outperformed the S&P 500 proxy SPY, which fell 0.30% to $767.02 on the session.
Why are investors rotating toward dividend payers now?
The driver cited is valuation anxiety around the artificial-intelligence trade. When investors grow uneasy about paying high multiples for growth, cash-generative businesses that return money to shareholders regularly become a hedge. The dividend provides a return that does not depend on multiple expansion continuing.
Does a higher yield mean a better income investment?
Not necessarily. A high headline yield often reflects the market pricing in risk — a stretched payout ratio, sector pressure or a patent cliff. A lower yield that grows each year can deliver more total income over a decade than a static higher one. Coverage from free cash flow is the more important test.
What makes each company's cash flow different?
AT&T's cash comes from recurring subscription bills but is consumed heavily by network capital spending. ONEOK operates midstream energy assets on fee-based contracts, which dampens commodity price swings. Pfizer generates high-margin cash from patented drugs, which is lucrative but exposed to patent expiry and pipeline outcomes.
How did the broader market perform that day?
The S&P 500 proxy SPY fell 0.30% to $767.02, and the Dow 30 proxy DIA dropped 0.65% to $531.57. The Nasdaq 100 proxy QQQ was roughly flat, up 0.05% at $716.76. That pattern suggests growth stocks stopped leading rather than breaking down outright.
Sources
Photo: olia danilevich · Pexels Licence — source
